Core Insights - Bionano Genomics showcased the advancements of optical genome mapping (OGM) at the AMP Annual Meeting, emphasizing its superior ability to detect structural variants compared to traditional methods [1][4] - The conference featured thirteen studies demonstrating OGM's effectiveness in identifying clinically relevant structural variants, highlighting its potential as a high-resolution technique for understanding complex diseases [2][3] Group 1: OGM Utility and Applications - OGM has been integrated into laboratory workflows, enhancing its application in clinical and translational research settings [3] - Key studies presented included applications of OGM in recurrent pregnancy loss, pediatric low-grade gliomas, and various hematological malignancies [3] Group 2: Research Highlights - Notable presentations included the use of OGM for genome-wide structural variant detection in fresh-frozen tissue and its complementarity with next-generation sequencing in multiple myeloma [3] - The studies collectively illustrate OGM's capacity to uncover genetic mechanisms driving diseases, reinforcing its role in modern genomics [2][3] Group 3: Company Commitment - Bionano Genomics is dedicated to innovating and expanding its OGM platform, aiming to make comprehensive structural variant analysis routine and accessible [4]

Core Insights - Bionano Genomics reported a total revenue of $7.4 million for Q3 2025, marking a 21% increase from $6.1 million in Q3 2024, despite a prior year write-down of $0.5 million in clinical services revenue [5][20] - The company has shifted its business model to focus on consumables and software utilization, which has led to improved margins and reduced operating expenses [2][5] - Bionano's gross margin for Q3 2025 was 46%, a significant recovery from (139)% in Q3 2024, indicating a positive trend in financial performance [5][20] Financial Performance - Total revenue for Q3 2025 was $7.4 million, up 21% from $6.1 million in Q3 2024 [5] - Consumables and software revenues increased by 15% year-over-year [5] - Operating expenses were reduced by 66% to $11.9 million, and non-GAAP operating expenses decreased by 40% to $9.7 million [5][20] - The company ended Q3 2025 with cash and equivalents totaling $31.8 million [5] Business Highlights - Bionano sold 8,390 nanochannel array flowcells in Q3 2025, a 7% increase from 7,835 flowcells sold in Q3 2024 [5] - The installed base of optical genome mapping (OGM) systems reached 384, a 4% increase from 368 systems at the end of Q3 2024 [5] - The company completed a public offering in September 2025, raising $10 million in gross proceeds [6] Market Outlook - Bionano anticipates Q4 2025 revenue in the range of $7.5 to $7.9 million and full-year revenue between $26.0 to $30.0 million [11] - The company expects to install over 25 new OGM systems in 2025, exceeding previous expectations of 20 to 25 installations [11]

Core Viewpoint - Bionano Genomics, Inc. has successfully closed a public offering, raising approximately $10 million, with potential additional proceeds of around $20 million from Series Warrants if fully exercised [1][3]. Group 1: Offering Details - The public offering consisted of 5,000,000 shares of common stock and Series E and Series F warrants, all priced at $2.00 per share [1]. - The Series E warrants will expire five years after issuance, while the Series F warrants will expire eighteen months after issuance [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. Group 2: Financial Implications - The gross proceeds from the offering were approximately $10 million before deducting fees and expenses [3]. - If the Series Warrants are fully exercised, the potential additional gross proceeds could reach approximately $20 million [3]. - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions and offers diagnostic services and software [6]. - Bionano's mission is to transform genome analysis through innovative technologies, including proprietary isotachophoresis (ITP) [6].

Company Overview - Bionano Genomics, Inc. is a provider of genome analysis solutions aimed at addressing complex questions in biology and medicine [3] - The company's mission is to transform genome visualization through optical genome mapping (OGM) solutions, diagnostic services, and software [3] - Bionano offers OGM solutions applicable in basic, translational, and clinical research, along with a platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis (ITP) technology [3] Upcoming Conference - Erik Holmlin, PhD, the CEO of Bionano, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1] - The presentation is scheduled from 3:00 p.m. to 3:30 p.m. ET [2] - A recording of the session will be available on the Bionano website for at least 30 days following the conference [2]

Core Insights - Bionano Genomics, Inc. announced a peer-reviewed publication demonstrating that optical genome mapping (OGM) is an accurate and cost-effective method for detecting and sizing large repeat expansions linked to 40 genetic disorders [1][3] - The study evaluated 85 subjects with known pathogenic expansions in three genes, providing a comprehensive assessment of OGM's capabilities [1][4] Group 1: Study Findings - OGM identified 84 out of 85 pathogenic repeat expansions, achieving a detection accuracy of 98.8% [7] - OGM measured repeat sizes accurately, even for expansions exceeding 7,000 repeat units, indicating no apparent upper size limit [7] - Evidence of somatic instability was found in 36 out of 85 samples, with variability observed in 30% of DMPK samples, 92% of CNBP samples, and 16% of RFC1 samples [7] Group 2: Methodological Advantages - OGM provides a single technique workflow that detects large repeat expansions across multiple loci, potentially reducing turnaround times and lowering costs compared to traditional methods [4][7] - The study highlights OGM's potential to address long-standing challenges in genome analysis, including structural variation and repeat expansion detection [3][4] Group 3: Company Overview - Bionano is a provider of genome analysis solutions aimed at transforming the understanding of the genome through OGM solutions, diagnostic services, and software [5] - The company offers OGM solutions for various applications in basic, translational, and clinical research, along with industry-leading genome analysis software [5]